Ikonisys SA announced the start of its first distribution collaboration for the sale of the Ikoniscope20 Digital Fluorescence Microscope Solution in the Eastern European Market. As announced during the IPO of Ikonisys, the commercialization strategy of Ikonisys will focus on a direct /non-direct sales model, being direct with its own sales force in the United States and major European countries, and working with qualified distributors that have a strong market presence in the field of Molecular Pathology in their respective markets. The partnership with BioVendor will focus on their home-markets, Czech and Slovak Republics, at first, with the potential to extend the collaboration to Austria and the United Kingdom at a later time.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.43 EUR | 0.00% | 0.00% | -8.33% |
Feb. 19 | Ikonisys Says Hospitex Wins Italian Tender for Diagnostic Systems | MT |
Jan. 02 | Ikonisys: production record for Hospitex | CF |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-8.33% | 16.01M | |
+0.89% | 12.59B | |
-12.53% | 7.42B | |
+1.78% | 5.35B | |
-1.16% | 4.51B | |
+5.68% | 4.47B | |
-50.87% | 3.21B | |
+11.34% | 2.71B | |
-16.13% | 1.96B | |
-11.07% | 1.73B |
- Stock Market
- Equities
- ALIKO Stock
- News Ikonisys S.A.
- Ikonisys Announces the Start of a Distribution Collaboration with BioVendor Laboratory Medicine for Distribution of the Ikoniscope20 System in the Eastern European Market